Literature DB >> 32377173

Resistance patterns of refractory H. pylori infection in a referral center in the Delaware Valley.

Shria Kumar1, Ravindra Sangitha2, Irving Nachamkin3, David C Metz1.   

Abstract

INTRODUCTION: H. pylori (HP) resistance is increasing in the US. Guidelines suggest treatment based on local resistance patterns, yet are poorly studied. We describe resistance patterns of the Delaware Valley.
METHODS: A retrospective study of patients referred to the Hospital of the University of Pennsylvania, between 2009-2019 who underwent endoscopy for culture. Chart review identified demographics, history, endoscopic and culture results, treatment, and follow up.
RESULTS: Of 109 patients referred for refractory HP, 90 had identified HP. Median age was 53.2 years and the majority was female (74%), with median 2 previous antibiotic courses for HP. Gastric erythema was the most common endoscopic abnormality. 65 (72.2%) were culture positive, and 45 (69.2%) were resistant to levofloxacin, 27 (41.5%) to metronidazole, and 39 (43.3%) to clarithromycin.Being resistant to any one of the 3 antibiotics was associated with resistance to either of the other two. There was an association with number of previous antibiotics with resistance (OR 1.74, p<0.05).We prescribed therapy to 77 patients based on susceptibility profiles, and 34 (37.8%) were cured, 14 (15.6%) underwent endoscopic surveillance, 3 (3.3%) were followed by infectious disease, and 39 (43.3%) were lost to follow up.
CONCLUSIONS: Antibiotic resistance is associated with refractory HP, and continues to rise. Culturing is associated with cure, and its use in clinical practice regarding efficacy, cost-effectiveness, and ability to minimize antibiotic resistance should be further studied. Overall follow-up is limited by loss to follow up, emphasizing the need for appropriate treatment.

Entities:  

Keywords:  H. pylori; antibiotic resistance; culture and susceptibility

Year:  2019        PMID: 32377173      PMCID: PMC7202550          DOI: 10.1002/ygh2.382

Source DB:  PubMed          Journal:  GastroHep        ISSN: 1478-1239


  28 in total

Review 1.  Helicobacter pylori Infection.

Authors:  Sheila E Crowe
Journal:  N Engl J Med       Date:  2019-03-21       Impact factor: 91.245

2.  Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Hitoshi Tsugawa; Seiichiro Fukuhara; Sawako Miyoshi; Kenro Hirata; Takashi Seino; Misako Matsushita; Toshihiro Nishizawa; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2015-11-13       Impact factor: 4.623

Review 3.  Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications.

Authors:  Monique M Gerrits; Arnoud H M van Vliet; Ernst J Kuipers; Johannes G Kusters
Journal:  Lancet Infect Dis       Date:  2006-11       Impact factor: 25.071

4.  Role of MIC levels of resistance to clarithromycin and metronidazole in Helicobacter pylori eradication.

Authors:  Vincenzo De Francesco; Angelo Zullo; Giulia Fiorini; Ilaria M Saracino; Matteo Pavoni; Dino Vaira
Journal:  J Antimicrob Chemother       Date:  2019-03-01       Impact factor: 5.790

Review 5.  Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.

Authors:  J P Gisbert; X Calvet
Journal:  Aliment Pharmacol Ther       Date:  2011-11-30       Impact factor: 8.171

6.  Systematic review: Would susceptibility-guided treatment achieve acceptable cure rates for second-line Helicobacter pylori therapy as currently practiced?

Authors:  Mireia Baylina; Neus Muñoz; Jordi Sánchez-Delgado; Sheila López-Góngora; Xavier Calvet; Ignasi Puig
Journal:  Helicobacter       Date:  2019-04-16       Impact factor: 5.753

7.  Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin.

Authors:  S Toracchio; S Capodicasa; D B Soraja; L Cellini; L Marzio
Journal:  Dig Liver Dis       Date:  2005-01       Impact factor: 4.088

8.  Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System.

Authors:  H M El-Zimaity; D Y Graham
Journal:  Hum Pathol       Date:  1999-01       Impact factor: 3.466

Review 9.  Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions.

Authors:  Alessia Savoldi; Elena Carrara; David Y Graham; Michela Conti; Evelina Tacconelli
Journal:  Gastroenterology       Date:  2018-07-07       Impact factor: 22.682

Review 10.  Helicobacter pylori therapy: a paradigm shift.

Authors:  David Y Graham; Maria Pina Dore
Journal:  Expert Rev Anti Infect Ther       Date:  2016-05-03       Impact factor: 5.091

View more
  1 in total

Review 1.  Clinical Factors Implicated in Antibiotic Resistance in Helicobacter pylori Patients.

Authors:  Brian White; Maria Winte; Joshua DeSipio; Sangita Phadtare
Journal:  Microorganisms       Date:  2022-01-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.